Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Smętna 12 Street, PL, 31-343, Kraków, Poland.
Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Smętna 12 Street, PL, 31-343, Kraków, Poland.
Neuropharmacology. 2018 Oct;141:223-237. doi: 10.1016/j.neuropharm.2018.08.035. Epub 2018 Aug 28.
A specific activation of metabotropic glutamate receptor 7 (mGluR7) has been shown to be neuroprotective in various models of neuronal cell damage, however, its role in glia cell survival has not been studied, yet. Thus, we performed comparative experiments estimating protective effects of the mGluR7 allosteric agonist AMN082 in glia, neuronal and neuronal-glia cell cultures against various harmful stimuli. First, the transcript levels of mGluR7 and other subtypes of group II and III mGluRs in cortical neuronal, neuronal-glia and glia cell cultures have been measured by qPCR method. Next, we demonstrated that AMN082 with similar efficiency attenuated the glia cell damage evoked by staurosporine (St) and doxorubicin (Dox). The AMN082-mediated glioprotection was mGluR7-dependent and associated with decreased DNA fragmentation without involvement of caspase-3 inhibition. Moreover, the inhibitors of PI3K/Akt and MAPK/ERK1/2 pathways blocked the protective effect of AMN082. In neuronal and neuronal-glia cell cultures in the model of glutamate (Glu)- but not St-evoked cell damage, we showed a significant glia contribution to mGluR7-mediated neuroprotection. Finally, by using glia and neuronal cells derived from mGluR7+/+ and mGluR7-/- mice we demonstrated a higher cell-damaging effect of St and Dox in mGluR7-deficient glia but not in neurons (cerebellar granule cells). Our present data showed for the first time a glioprotective potential of AMN082 underlain by mechanisms involving the activation of PI3K/Akt and MAPK/ERK1/2 pathways and pro-survival role of mGluR7 in glia cells. These findings together with the confirmed neuroprotective properties of AMN082 justify further research on mGluR7-targeted therapies for various CNS disorders.
已证实,在各种神经元细胞损伤模型中,代谢型谷氨酸受体 7(mGluR7)的特定激活具有神经保护作用,但其在神经胶质细胞存活中的作用尚未得到研究。因此,我们进行了比较实验,评估了 mGluR7 变构激动剂 AMN082 在胶质细胞、神经元和神经元-胶质细胞培养物中对各种有害刺激的保护作用。首先,通过 qPCR 方法测量了皮质神经元、神经元-胶质和胶质细胞培养物中 mGluR7 和其他 II 组和 III 组 mGluR 亚型的转录水平。接下来,我们证明 AMN082 以相似的效率减弱了星形孢菌素(St)和阿霉素(Dox)引起的胶质细胞损伤。AMN082 介导的神经保护作用依赖于 mGluR7,与 caspase-3 抑制无关,与 DNA 片段化减少有关。此外,PI3K/Akt 和 MAPK/ERK1/2 通路的抑制剂阻断了 AMN082 的保护作用。在谷氨酸(Glu)而不是 St 诱导的细胞损伤模型中,我们在神经元和神经元-胶质细胞培养物中显示出 mGluR7 介导的神经保护作用中胶质细胞的显著贡献。最后,通过使用源自 mGluR7+/+和 mGluR7-/-小鼠的胶质细胞和神经元细胞,我们证明了 St 和 Dox 在 mGluR7 缺陷型胶质细胞中具有更高的细胞损伤作用,但在神经元(小脑颗粒细胞)中没有。我们的研究结果首次表明,AMN082 的神经保护作用和神经保护作用涉及激活 PI3K/Akt 和 MAPK/ERK1/2 通路以及 mGluR7 在神经胶质细胞中的生存作用。这些发现以及 AMN082 已证实的神经保护特性证明了针对各种中枢神经系统疾病的 mGluR7 靶向治疗的进一步研究是合理的。